Bhi corporate overview november 2019

For Prospective Professional Investors/Qualified Investors only – Proprietary & Confidential
0
Corporate Overview
November 2019

1
Private Company Disclosure
This Confidential Investor Presentation (the ‘Presentation Is being delivered to a select number of parties who have expressed an interest in
pursuing a business or financial relationship with Blue Horizon International AG. Nothing contained within this Presentation alone is an offer
to buy or sell securities or an offering of any product, service or fund. An offer to buy or sell securities will only be accompanied by appropriate
documents including, but not limited to, a private placement memorandum or Offering Circular which will contain, among other things, a
listing of possible risk factors associated with the securities being offered. All representations and warranties are hereby disclaimed. The
Information contained in this presentation is intended for general Informational purposes only and is not Intended to be information sufficient
for the making of a business or investment decision. While reasonable efforts have been made to ensure that the information contained in this
Presentation has been obtained from sources deemed to be reliable, Blue Horizon International AG does not guaranty that the information
contained herein is accurate or complete and is not responsible for any errors or omissions, or for the results obtained from the use of this
information. All information in this Presentation is provided “as is” with no guarantee of completeness, accuracy, timeliness or of the results
obtained from the use of this Information, and without warranty or representation of any kind, statutory, express, or implied, oral or written. In
no event will Blue Horizon International AG, its related entities, or its members, partners, agents or employees be liable to you or anyone else
for any decision made or action taken in reliance on the information in this Presentation alone or for any consequential, special or similar
damages, even if advised of the possibility of such damages. You should conduct your own due diligence with respect to any and all information
related to this document and the offering in the private placement memorandum or Offering Circular and are not entitled to rely solely on the
information in this Presentation. Further, Blue Horizon International AG is under no obligation to update the material or information
presented herein even if they later become aware that such information or material is no longer accurate or true. Any recipient of this
Presentation assumes all risk in, and Blue Horizon International AG will not be liable for any damages arising out of, use of information
including. without limitation, business decisions made or inferences drawn by anyone in reliance on the Presentation at the fact of the disclosure
of the information. All communications or inquiries relating to Blue Horizon International AG should be directed to Brian Mehling at 866-263-
2479 or by email to mehling@rcn.com.

2
Table of Contents
1. Corporate Overview
2. Markets & Opportunities
3. Safety & Research
Information
4. BHI Charitable
Foundation & Patient
Testimonials
5. US Affiliate Company,
BHI Therapeutic
Sciences
Introduction to BHI and Dr. Brian Mehling
Outline of the opportunities for stem cell treatment and
medical truism
Walkthrough of several BHI conducted studies that
provide information on the safety and therapeutic effects
of stem cell treatments on patients
Overview of BHI’s expansion into the US Market
Insight into multiple success stories from patients of BHI’s
procedures and the company’s ongoing efforts to bring
affordable stem cell treatments to the broader public

3
Corporate Overview
Introduction to BHI and Dr. Brian Mehling
1. Corporate Overview

4
Blue Horizon: Corporate Overview
Blue Horizon
International AG
was formed in 2017
to monetize stem
cell technology
and associated
regenerative medicine
Blue Horizon is focused on using stem cells to treat a wide
range of diseases and to provide health benefits without the
use of drugs or surgery.
The company has an established manufacturing process for
the necessary supply of stem cells and understands the
treatment procedures via its clinical practices.

5
Founder Dr. Brian Mehling MD, MS
Dr. Brian Mehling, MD, MS
Founder & Chief Medical Officer
Brian Mehling, M.D., M.S. is the founder and chief medical officer of Blue Horizon International
(BHI). He is a practicing American orthopedic trauma surgeon, researcher, and philanthropist.
Dr. Mehling started his path in medicine through undergraduate study at Harvard University,
obtaining his Bachelor of Arts and Master of Science degrees in Biochemistry from Ohio State
University. Completing his degree of medicine at Wright State University School of Medicine, Dr.
Mehling received post graduate education through residencies and fellowships at St. Joseph’s
Hospital in Paterson, NJ and the Graduate Hospital in Philadelphia, PA, while pursuing a Ph.D. in
Chemistry.
Educational Background
Dr. Mehling has traveled extensively throughout Asia and the Middle East observing firsthand the
differences in healthcare standards. Identifying the need for a universal high quality standard, he
founded Blue Horizon International.
Global Perspective
Dr. Mehling founded the Blue Horizon Charitable Foundation, which was with the mission to assist
in and finance the advancement of all aspects of stem cell therapies and cellular regenerative
medicine and research in full regulatory conformance, in conjunction with the scientific community.
The foundation will also support and provide charitable therapies to those suffering from
degenerative diseases and debilitating conditions.
He and his colleagues have successfully treated and monitored more than 600 patients using stem cell
and regenerative therapies. Patients have been treated for a wide range of diseases and disorders
including spinal cord injury and cerebral palsy.
Stem Cell Pioneer
Charitable Founder

6
Founder, Chief Medical Officer, MD, MS
 Internationally known, board-certified orthopedic
trauma surgeon
 Operates own practice, Mehling Orthopedics, in West
Islip, NY and Hackensack, NJ
 Undergone 30+ stem cell therapies himself in the last
7 years
 Harvard University undergraduate
Chief Executive Officer
 23 years of experience in healthcare management
 Served as Senior Vice President of Operations at
Hackensack University Medical Center
 Registered nurse with a Masters of Science degree in
Health Administration
Chief Financial Officer
 Over 30 years of experience in accounting and finance
 Spent 16 years as a CFO
Chief Science Officer, MD, PhD
 Professor at Wuhan University School of Basic Medical
Science
 Chu Tian Scholar
 Leading expert in stem cell mechanics
 Focus on designing clinical trials using stem cells to treat
spinal cord injury
Director of Cultural Relations
 Guides Blue Horizon’s community and stakeholder
relationships
 Serves as chairman of the unaffiliated not-for-profit
company, Blue Horizon Charitable Foundation
Clinical Research Scientist
 Doctor of Philosophy (PhD) in Biological Sciences
 Postdoctoral education at the Institute of Human Genetics,
University Hospital Jena, Germany
 Fifteen years of experience in biomedical research, five years
of experience in clinical research
 Author of over 40 research papers in peer-reviewed journals
Dr. Brian Mehling
Dr. Dongcheng Wu
Doreen Santora
Eddie Amarante
John Pape
Marine
Manvelyan
Successfully treated and monitored 600+ subjects
using stem cell therapies
Katarina
Novokova
President, BHI Slovakia
 Oversees Blue Horizon’s operations in Slovakia
 Director of relations od Blue Horizon Charitable
Foundation
 Nominee for the Economic World Forum’s Young
Global Leaders (Class of 2019) Klara Doert
President, Business Development
 Oversees Blue Horizon’s Stem Cell and Skin Care business
development
 20 years of leadership experience in cosmeceuticals, spa, medical
spa, and alternative therapy industries in Europe, the United
States of America, and Asia.
 Director of the Global Healthcare Forum of Diplomatic Council
Leadership Team

7
Scientific Advisory Board
 Cognitive neuroscientist and
entrepreneur affiliated with Harlem
Biospace, the first biotechnology startup
incubator in New York City.
 Founding director of the biomedical
accelerator facility at Mount Sinai School
of Medicine, NY
 Medical Professor at the Sophie Davis
Medical SchoolAndre Ragnauth, Ph.D.
 Professor at Wuhan University School of
Basic Medical Science
 Chu Tian Scholar
 Leading expert in stem cell mechanics
 Focus on designing clinical trials using
stem cells to treat spinal cord injury
Dongcheng Wu, M.D., Ph.D.,
Chief Science Officer
 James S. Riepe University Professor;
Department of Neuroscience
 Perelman School of Medicine;
Department of Psychology, School of
Arts and Sciences
 Marketing Department, The Wharton
School, University of Pennsylvania
Michael Platt, M.D.
 Cancer scientist at the Keck School of
Medicine of USC in Los Angeles, California
 Specialized in neurodevelopment, cell
signaling, cancer stem cell, pre-clinical
development, and molecular targeted therapy
for cancer treatment.
 Ph.D., Keck School of Medicine of USC
 B.S., B.A., Mount Saint Mary’s College
Vicky Yamamoto, Ph.D.
Jason Dictenberg, PhD
 CEO and Chief Scientist, AccelBio LLC
 Research Associate Professor, SUNY
Downstate Medical Center
 Ph.D., Molecular Medicine, University of
Massachusetts Medical School/Harvard
Medical School
 B.A., Molecular Biology and Genetics,
Highest Honors in Research, Brandeis
University
Joseph Feldman, M.D.
 Board-certified emergency medicine
physician in NY and NJ
 Current medical director at Mount Sinai
Urgen Care and former chairman of the
Emergency/Trauma Center at
Hackensack University Medical Center
 Author of several publications and
books.

8
An Expanding Global Presence
Slovakia
 100% BHI owned clinic
 $5,000 charge per treatment
 Located on the outskirts of Bratislava
Jamaica
 65% BHI owned clinic
 Jamaica is the largest English-speaking Caribbean
Island
 Positioned to take advantage of medical tourism
 Typically $5,000 per therapy
 GMP-certified facility
 US board-certified physicians on staff
Wuhan, China
 More than 3,000 patients have been successfully
treated in the Stem Cells Therapy Center at Wuhan
Hong Qiao Brain Hospital
 Treatments have focused on spinal cord injury, brain
trauma, stroke, cerebral palsy, brain disease,
encephalitis, and several kinds of nervous
degenerative diseases
Global clinics operating (outside United States):
Blue Horizon aims to launch more
100% owned locations as well as
additional partnerships

9
Historical Start-up & Test Phase Revenues
$94,400
$170,410
$123,538
$248,127
$0
$50,000
$100,000
$150,000
$200,000
$250,000
$300,000
2015 2016 2017 2018
Notes to Historical Revenues
 Includes only revenues from
payments received
 Company benefited from patients
that participated in early procedures –
even if payment was never received
by patient and/or insurance company
 Company/affiliates have preformed
over 650 procedures
 Growth phase to commence upon
completion of 2Q2019 capital raise

10
Financial Projections
Blue Horizon International AG 2020 2021 2022 2023 2024
(Projected) (Projected) (Projected) (Projected) (Projected)
Revenue 617,980$ 2,072,750$ 4,546,623$ 10,277,808$ 23,754,011$
Costs & Expenses
Cost of Goods Sold 271,911$ 912,010$ 2,000,514$ 4,522,236$ 10,451,765$
General & Administrative 210,253$ 562,526$ 683,754$ 831,107$ 1,010,215$
Marketing 212,364$ 580,695$ 733,114$ 925,539$ 1,168,472$
Depreciation & Amortization 17,500$ 65,733$ 59,402$ 53,681$ 48,511$
R&D 129,304$ 157,170$ 191,041$ 232,211$ 282,254$
Total Cost & Expenses 841,332$ 2,278,133$ 3,667,824$ 6,564,773$ 12,961,217$
Income from Operation (223,352)$ (205,383)$ 878,799$ 3,713,035$ 10,792,795$
Pre-tax Income (223,352)$ (205,383)$ 878,799$ 3,713,035$ 10,792,795$
Provision for Income Tax1
-$ -$ 126,018$ 1,039,650$ 3,021,982$
Net Income (223,352)$ (205,383)$ 752,781$ 2,673,385$ 7,770,812$
EBITDA
2
(205,852)$ (139,650)$ 938,201$ 3,766,716$ 10,841,305$
1
Based on estimated corporate tax rate and customary treatment of tax-loss carryforward
2
EBITDA is not generally considered GAAP accounting
Note: Projections are dependent upon reasonably timed funding, relate to future performance, and reflect expectations at the time
this presentation was prepared and are subject to risks, uncertainties and assumptions that may cause these projections
to differ materially from actual results. We can provide no assurance that these expectations will prove to be correct and
these financial projections should not be unduly relied upon.

11
Financial Projections For Additional Single Clinic
Year One
(Projected)
Year Two
(Projected)
Year Three
(Projected)
Year Four
(Projected)
Year Five
(Projected)
Number of Patients 100 200 400 800 1600
Gross Stem Cell Revenue $ 500,000 $ 1,000,000 $ 2,000,000 $ 4,000,000 $ 8,000,000
Net Profit Before Tax $100 Repayed to Hospital $ 250,000 $ 600,000 $ 1,400,000 $ 3,200,000
Hospital Share Before Tax No Effective Net Profit $ 104,500 $ 250,800 $ 585,200 $ 1,337,600
Estimated Ancillary Services $ 50,000 $ 100,000 $ 200,000 $ 400,000 $ 800,000
1Based on estimated corporate tax rate
and customary treatment of tax-loss
carry forward
2EBITDA is not generally considered
GAAP accounting
Note: Projections are dependent upon
reasonably timed funding, relate to
future performance, and reflect
expectations at the time this
presentation was prepared. Projections
are subject to risks, uncertainties, and
assumptions that may cause these
projections to differ materially from the
actual results. We can provide no
assurance that these expectations will
prove to be correct and these financial
projections should not be unduly relied
upon.

12
Markets & Opportunities
Outline of the opportunities for stem cell treatment
and medical truism
2. Markets & Opportunities

13
Stem Cell Market Opportunity
Blue Horizon is
working to bring the
miracle of life saving
stem cell treatments
to the world
We address widespread medical conditions, including…
(1) According to the US Centers for Disease Control and Prevention and the World Health Organization
(2) According to the Alzheimer's Association and Alzheimer's Disease International
15 million people suffer a stroke each year worldwide. In the United States,
nearly 800,000 people suffer from a stroke annually, making it the leading
cause of serious, long term disability in the US and the United Kingdom(1)
An estimated 50 million people, including 5.5 million Americans, suffer from
Alzheimer’s and other related dementias(2)
422 million people worldwide, including 29 million Americans, have diabetes,
with another estimated 8.1 million Americans undiagnosed, living unaware of
their condition(1)
7.2 million people worldwide, including 610,000 Americans, die each year
from heart disease(1)
54.4 million people in the U.S suffer from arthritis(1)
Stroke
Alzheimer’s Disease
Heart Disease
Arthritis
Diabetes

14
About Stem Cells
Stem cells have the remarkable potential
to develop into many different cell types
in the body. They can be used to
regenerate the human body without
drugs or surgery
 Treatment initiated over 50 years ago
 Originated from bone marrow transfers
 Stem cells regularly divide to repair and replace worn out or damaged
tissue
 Due to legal and ethical issues of using embryonic cells, Blue Horizon
uses placenta cord tissue from healthy babies – without any injury to
baby or mother
 Other source of stem cells is from patients themselves
Origin of Stem Cells
 Retrospective chart review studies of human umbilical cord blood derived
mononuclear cell therapy in subjects with spinal cord injury, stroke, and chronic
inflammation
 Retrospective chart review study of human adipose tissue derived mononuclear
cell therapy in subjects with musculoskeletal conditions
 Safety study of allogeneic cord blood hematopoietic progenitor cell therapy of
subjects with chronic inflammation (not yet initiated)
Research Studies in Regenerative Medicine
 Bring down long term medical costs
 Alleviate Suffering
 Potential to repair damage on all parts of body which have not yet been repaired
 No medication required- holistic approach
Overall advantages of stem cells

15
Stem Cell Extraction Methods
Umbilical Cord Blood (UCB)
 Rich source of hematopoietic stem cells and progenitor cells as well as non-hematopoietic stem cells
 Can be directly used after isolation without expansion
 The human leukocyte antigen type does not need a closely matched donor for non-hematopoietic
purposes as these cells are less likely to induce immunological reactions
Autologus Stem Cells
 Removal of adipose tissue under local anesthesia
 Lipoaspirate after extraction
 Isolation of stromal vascular fraction with MSCs
 Preparation ready for administration
 Administration of preparation into the hip or knee joint
Wharton’s Jelly (WJ)
 Expanded MSCs from WJ of healthy donors who underwent elective full-term pregnancy caesarean
sections
 Umbilical Cord is collected from primiparous pregnant women receiving caesarean section in
accordance with the sterile procedure guidelines in each hospital– no injury to the baby or mother
Treatment Modalities
 Intravenous infusion for peripheral injury or disease
 Intrathecal injection – for central nervous system pathology
 Intra-articular injection – for joint pathology

16
Global Medical Tourism Market Opportunity
Blue Horizon is
poised to capture not
only the opportunities
in the stem cell arena,
but will also be
positively impacted by
tremendous growth of
the global medical
tourism industry
*Statics are according to Patients Beyond Boards. www.patientsbeyondborders.com
Global Medical Tourism market size is estimated to be USD
65-87.5 billion, based on approximately 20-24 million cross-
border patients worldwide spending an average of USD $3410
per visit
With the world population aging and becoming more affluent at
rates that surpass the availability of quality healthcare resources,
it is anticipated that the market will growth at a rate of 15-25%
annually
It is projected that some 1.9 million Americans will travel
outside the US for medical care this year (2019), where
projected savings are estimated to be in the 30 to 60 percent
range for the top destinations

17
Safety & Research Information
Walkthrough of several BHI conducted studies that provide
information on the safety and therapeutic effects of stem cell
treatments on patients
3. Safety & Research Information

18
Safety of BHI Stem Cell Therapy
• BHI has taken every precaution to ensure the safety and
viability of their stem cell treatments, having successfully
treated more than 600 patients and documenting each
procedure.
• Ongoing long-term safety study of 30 research subjects
who received hUCB stem cell therapy is underway, where
preliminary results indicate that 17 research subjects did
not develop adverse effects/medical conditions related to
the therapy 4-7 years after administration.
• Research published in “Experimental and therapeutic
medicine” cited at PubMed Central, US National Library
of Medicine, National Institutes of Health; “CellR4”, the
official journal of The Cure Alliance; and presented at the
American Academy of Orthopedic Surgeons.
• Stem cells evaluated in clinical studies are collected in
accordance with Good Tissue Practice to ensure safety
and have been approved by the Investigational Research
Board and in accordance with Good Clinical Practice.

19
Retrospective cohort study for Spinal Cord Injury (SCI) subjects
Analyze muscle, nerve, urinary, and gastrointestinal functions
in SCI subjects treated with human Umbilical Cord Blood
Mononuclear Cells (hUCB-MNCs) versus conventional
therapy
Goal
-30 subjects with SCI were randomly selected from 70
treated with hUCMNCs between March 2009 and March
2012 in Wuhan Hongqiao Brain Hospital, a longtime BHI
partner, and using BHI’s stem cell treatment procedures.
-Another 30 subjects with SCI received only traditional
therapy and no stem cell therapy
Subjects and Location
- Approved by the Institutional Review Board (Office of
Research and Sponsored Programs. SC#5488, April 2, 2014).
- Results published in peer-reviewed journal, CellR4, in 2018
Approval and publications
0
5
10
15
20
25
30
Pre Post Pre Post
NumberofSubjects
None Normal
Stem Cell Therapy Traditional Therapy Only
Changes in ability to sense pain
0
5
10
15
20
25
30
Pre Post Pre Post
NumberofSubjects
None Normal
Traditional TherapyStem Cell Therapy
Changes in ability to sense temperature
Results

20
Retrospective cohort study for Spinal Cord Injury (SCI) subjects (Continued)
0
5
10
15
20
25
30
35
Pre Post Pre Post
NumberpfSubjects
LLM=0 LLM=1 LLM=2
Results (cont.)
Changes in lower limb muscle (LLM) strength*
0
5
10
15
20
25
30
35
Pre Post Pre Post
NumberofSubjects
Incontinence Catheterization Normal
Changes in bladder function
A significantly higher proportion of subjects in the stem cell therapy group showed improved function in pain and
temperature sensation, lower limb muscle strength, and bladder function, compared to the conventional therapy group.
* Utilized a non-traditional quantitative scoring system for strength

21
Retrospective cohort study for stroke subjects
Analyze impact of human Umbilical Cord Blood
Mononuclear Cells (hUCB-MNC) therapy on mobility and
muscle strength of upper and lower extremities, and
neurological function in subjects with ischemic and
hemorrhagic stroke.
Goal
97 subjects with ischemic and hemorrhagic stroke were
treated with human Umbilical Cord Blood Mononuclear
Cells (hUCB-MNCs) between March 2009 and March 2012
in Wuhan Hongqiao Brain Hospital, a longtime BHI partner,
and using BHI’s stem cell treatment procedures.
- Approved by Institutional Review Board (IRCM-2017-135,
January 18, 2017).
- Results are presented at the conference Adult Stem Cells
and Regenerative Medicine. The New York Academy of
Sciences, NY, 2019.
Results
0%
20%
40%
60%
80%
100%
1 2 3 4 5 6
Physical conditions
Percentage of improvement*
* Percentage of aubjects that reported post-treatment improvement of the
following conditions after having reported suffering from such conditions prior
to treatment
1. Upper extremity mobility
2. Lower extremity mobility
3. Neurological function (ability to speak)
4. Upper extremity muscle strength
5. Lower extremity muscle strength
6. Neurological function (urinary and bowel function)

22
Retrospective cohort study for arthritis subjects
Analyze changes in pain and mobility of research subjects
with osteoarthritis and rheumatoid arthritis after receiving
treatment with stem cells derived from adipose tissue.
Goal
350 subjects underwent the therapy with their own cells at
the Malacky Hospital in Bratislava, Slovakia, a partner of a
BHI affiliate
-Study was approved by the Ministry of Health of the Slovak Republic and by the Institutional Review Board (IRCM-2017-137, January
18, 2017)
- Results are presented at the American Academy of Orthopedic Surgeons Annual Meeting, New Orleans, Louisiana, 2018
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
7 days 3
months
6
months
12
months
Decrease
No Change
Increase
Changes in Pain after Therapy
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
7 days 3
months
6
months
12
months
Increase
No Change
Decrease
Changes in Mobility after Therapy
Results: Significant decrease in subjects’ pain sensation and improvement in subjects’ mobility were observed three,
six and 12 months comparing to seven days after therapy

23
Retrospective chart review study for subjects with chronic inflammation
Evaluate the safety of Human Cord Blood Derived
Mononuclear Cell (hUCBMC) therapy for subjects with
chronic inflammation and the effects on different health
indicators
Goal
30 research subjects received hUCBMC therapy in the period
2010-2013 in Hackensack, New Jersey under the direct purview
of BHI
- Study was approved by the Institutional Review Board (IRCM 2014-040, December 17, 2014)
- Results published in peer-reviewed journal CellR4 in 2015
Changes in Pain after Therapy
Results
0
10
20
30
40
50
60
70
80
90
100
Energy/fatigue Social
functioning
Pain General Health
Initial
3 months
6 months
Notes:
- A higher pain level indicator implies less physical
pain, and vice versa.
- Data indicate continued improvement over six
month period
- Preliminary results of blood test markers indicate
that research subjects did not develop any adverse
effects or adverse medical conditions over the six
month period

24
BHI Charitable Foundation & Patient
Testimonials
Insight into multiple success stories from patients of BHI’s
procedures and the company’s ongoing efforts to bring
affordable stem cell treatments to the broader public
4. BHI Charitable Foundation & Patient Testimonials

25
BHI Charitable Foundation
The Blue Horizon
Charitable Foundation
was formed with the
mission to assist in and
finance the
advancement of all
aspects of stem cell
therapies and cellular
regenerative medicine.
Dedicated to increasing the awareness of global inequalities in
healthcare, as well as providing charitable medical care and
education to adults and children in impoverished areas.
Raises capital in order to support medical centers and clinics
by providing medicines vital to basic human survival, by
performing advanced medical treatments otherwise not
accessible to certain geographic regions.
Produces documentary films that bring much needed
attention to the plight of those with limited or no access to
healthcare.

26
BHI Charitable Foundation: Gala Photos

27
Patient Testimonials With Video Links
“I was injured 20 years ago. I was in a
car accident driving to Florida with
some friends. My injury, C4, C5
incomplete, which means from the
chest down there's no movement...I do
believe that these stem cells are going
to make a big change. At least, in my
body, I've seen it, I'm very happy with
the progress because every time, it's
something new. Every time.”
Yesenia Torres, 45 years old
“ My twins were nine months old
when I was injured. So you miss a
lot of things if you're not able to get
on the floor and play with them -
really interact with them. Basically,
it gave me my life back.”
Jeremy Hogan, 40 years old
"I was severely injured in a car
accident. My car lost control and hit a
telephone pole. The whole transmission
went into my leg, which almost led to
amputation. After limb saving surgery,
Dr. Mehling introduced me to stem cells.
Soon, I felt the strength returning to my
calf muscle and started walking better. I
am on my back to living a normal life -
walking, driving, playing sports.”
David Berger, 26 years old
*Click pictures to view online video of testimonial ** Additional videos, click here: bluehorizonstemcells.com

28
US Affiliate Company: BHI
Therapeutic Sciences
Overview of BHI’s expansion into the US Market
5. US Affiliate Company BHI Therapeutics Sciences

29
BHI Therapeutic Sciences: Corporate Overview
BHI Therapeutic Sciences is opening up clinics across the US, where
they will be conducting FDA clinical trials in various indications based
on the research from the international business’s patients.
The company is also marketing a line of skin care products utilizing
the stem cell technology, Alpha Blue.
BHI Therapeutic
Sciences was formed
to capitalize on the
progress made by
the international
business and expand
into the US Market

30
BHI Therapeutic Sciences Efforts to Date
Clinic Locations:
 New Jersey clinic is already established and prepared to
perform trial procedures
 Planning to expand to Texas in order to take advantage
of legislation that allows a profit on research subjects
participating in clinical trials. Targeting late 2019, early
2021 for launch and planning to charge $10,000 per dose
for the procedures
BHI Successful Research Treatments:
 100 research subjects with chronic inflammation
 30 patients with spinal cord injury
 97 research stroke patients
 350 research subjects with musculoskeletal disorders
Regulatory Compliance Consulting Company:
• Signed contract with a Fortune 100 multinational
healthcare company which will oversee each trial

31
Stroke and follow-on FDA trials
 Have FDA approval to start Phase I trial
 Primary objective: evaluate the safety of Hematopoietic
Stem Cells (HPC), Cord Blood in subjects with acute
ischemic stroke
 Secondary objective: evaluate the efficacy of HPC,
Cord Blood in subjects with acute ischemic stroke
 Study starts with 10 research subjects, will then attempt
to get approval for more
 Obtained approval to charge cost of dose, cannot
charge profit. Estimated charge will be $5,000 per dose
 Three therapy sessions per research subject
 ClinicalTRials.gov Identifier: NCT03735277
The ability to charge subjects participating in
clinical trials offsets the overall cost of
obtaining FDA approval.
Stroke FDA Trial
 Third priority
 Could be completed quickly
 Study starts with 10 research subjects
 Stating timeline of 3 – 6 months
 Three therapy sessions per research subject
Diabetes Trial
 Planned trial following stroke trial
 Study starts with 10 research subjects
 Starting timeline of 3 - 6 months
 One therapy per research subject
 May be able to start receiving
insurance reimbursement for
procedure
Knee Osteoarthritis Associated Pain Trial
Additional trials to follow
Follow-on trials

32
 Cosmetic skin care line, produce
in Germany
 Contains more than 32 cytokines
and growth factors derived from
our human stem cell cultures
 BHI purchases Alpha Blu
products from affiliated entity
 75% gross margins
 Plan to partner with drop
shipper
What is Alpha Blu?
 Purpose is to evaluate the safety and efficacy of the product
 Stimulation of the natural skin production of elastin and collagen
 Leads to a dramatic reduction in oxidative stress
 Developed sunscreen that does not contain any cancer-causing chemicals
 Market could include balm to reduce scarring and stretch marks, and be used
for psoriasis
Research
 Approved by the Institutional Review Board
 Safety Study of Alpha Blu Skin Care Line Application for Skin Anti-
Aging (IRCM-2017-140, February 22, 2017)
 Safety Study of Post-Surgical Balm Application for Scar Reduction
(IRCM-2016-107, May 25, 2016)
Research Studies in Wound Healing and Skin Rejuvenation
 Kit contains four products, costs $100
(day, night, eye, and skin creams)
 Monthly recurring order costs $90
 Individual bottles cost $50 each
 Shipping costs $25
 Discount codes are promoted
Alpha Blu Pricing Alpha Blu Distribution
 Product being marketed to dermatology practices
 Sold direct to consumers via
www.alphabluskincare.com
 Also sold on Amazon
 Promoted on social media
 Currently moving website to Shopify platform for
better social media integration
(1) https://www.marketwatch.com/press-release/stem-cells-market-size-is-projected-to-be-around-us-297-billion-by-2022-2018-06-19
(2) https://www.healthline.com/health/stem-cell-research
Alpha Blu

33
1Based on estimated corporate tax
rate and customary treatment of
tax-loss carry forward
2EBITDA is not generally
considered GAAP accounting
Note: Projections are dependent
upon reasonably timed funding,
relate to future performance, and
reflect expectations at the time this
presentation was prepared.
Projections are subject to risks,
uncertainties, and assumptions
that may cause these projections to
differ materially from the actual
results. We can provide no
assurance that these expectations
will prove to be correct and these
financial projections should not be
unduly relied upon.
BHI Therapeutic Sciences, Inc. 2020 2021 2022 2023 2024
(projected) (projected) (projected) (projected) (projected)
Revenue
Revenue from Alpha Blue 499,338$ 753,844$ 916,302$ 1,113,770$ 1,353,795$
Revenue from Proceedures 1,950,000$ 6,800,000$ 7,260,000$ 9,750,728$ 17,363,628$
Total Revenue 2,449,338$ 7,553,844$ 8,176,302$ 10,864,498$ 18,717,423$
Costs & Expenses
Cost of Goods Sold 2,042,457$ 3,513,077$ 3,767,445$ 5,042,429$ 8,884,883$
General & Administrative 316,025$ 549,872$ 448,710$ 564,136$ 733,132$
Marketing 139,230$ 203,847$ 298,452$ 436,963$ 639,758$
Depreciation & Amortization 17,500$ 65,733$ 59,402$ 53,681$ 48,511$
R&D 129,304$ 157,170$ 191,041$ 232,211$ 282,254$
Total Cost & Expenses 2,644,516$ 4,489,698$ 4,765,050$ 6,329,421$ 10,588,538$
Income from Operation (195,179)$ 3,064,146$ 3,411,252$ 4,535,077$ 8,128,885$
Pre-tax Income (195,179)$ 3,064,146$ 3,411,252$ 4,535,077$ 8,128,885$
Provision for Income Tax1
-$ 803,311$ 955,151$ 1,269,822$ 2,276,088$
Net Income (195,179)$ 2,260,835$ 2,456,101$ 3,265,256$ 5,852,797$
EBITDA
2
(177,679)$ 3,129,879$ 3,470,654$ 4,588,758$ 8,177,396$
$(5,000,000)
$-
$5,000,000
$10,000,000
$15,000,000
$20,000,000
2020 2021 2022 2023 2024
Total Revenue
EBITDA
Net Income

34
(631) 893-3903

Bhi corporate overview november 2019

Recommended

Recommended

More Related Content

Similar to Bhi corporate overview november 2019

Similar to Bhi corporate overview november 2019 (20)

Recently uploaded

Recently uploaded (20)

Bhi corporate overview november 2019